Helsinn Group strengthens the Board with the appointment of Francesco Granata
LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that Dr. Francesco Granata will join the Board of Helsinn Group as a Non-Executive Director.
Dr. Francesco Granata has over 35 years’ experience in biopharmaceuticals, private equity, venture capital and board management. He is a senior advisor at Warburg Pincus International LLC and Chairman of Circassia Plc and a Board member of Italfarmaco, Prismic Pharmaceuticals and Quanta Ltd and Helsinn Investment Fund and is Chairman of the board at KKI. Dr Granata has served as a member of the Executive Committee at Biogen Idec (NASDAQ: BIIB), where he led global commercial and medical affairs until 2012, and as Group Vice President for Schering-Plough Europe and Canada. He has previously held senior management positions with Pfizer, Pharmacia and Dompé Biotec and a commercial management position with GlaxoSmithKline Plc. Dr. Granata started his pharmaceutical career in research and development.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said, “I am delighted to announce the appointment of Dr. Granata to the Board of Directors of Helsinn Group. Francesco has a unique breadth of experience across our industry, drawing on many senior roles in biopharma, including many at Board level, investment and finance, and he has already proved himself a key adviser and source of expertise to the Helsinn Investment Fund Team. I have come to value his expertise and strategic counsel very highly and I know he will provide an invaluable perspective on the opportunities and challenges Helsinn faces.”
Francesco Granata, added, “I am delighted and honoured to be joining the Board of Helsinn Group, which I have known for many years and had many productive interactions with. Helsinn has the benefits of more than 40 years working experience in helping patients, and more recently, in focusing on supporting people with cancer and is using its insights to support brand new approaches to cancer therapeutics and supportive care. I look forward to working with the Board to achieve the Group’s ambition of improve cancer patients’ quality of life around the world.”
ENDS
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.
For more information, please visit www.helsinn.com
For further information, please contact:
Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo
